Matthew Fowler
Articles
Patient-Reported Outcomes Demonstrate Satisfaction With Pembrolizumab in Advanced Cervical Cancer
March 27, 2022
Article
Data collected with patient-reported outcomes show that pembrolizumab, with or without bevacizumab, is associated with a favorable toxicity profile in effectively treating women with persistent, recurrent, or metastatic cervical cancer.
Neoadjuvant Enfortumab Vedotin Shows Potential in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
February 28, 2022
Article
Preliminary findings suggest that enfortumab vedotin may be an effective treatment option for cisplatin-ineligible patients with muscle-invasive bladder cancer.
Adding Nivolumab to Encorafenib/Cetuximab Yields High Response Rates in MSS, BRAF V600E+ CRC
January 24, 2022
Article
Encouraging response rates were observed among patients with BRAF V600E–mutant metastatic colorectal cancer who received a triplet regimen of nivolumab, encorafenib, and cetuximab.
Drug Combo Shows Early Activity in Pediatric Neuroblastoma Treatment
April 13, 2021
Article
Overall, 3 objective responses were recorded from 16 eligible patients in the neuroblastoma cohort, which met the protocol-defined efficacy end point.
Nurse Navigation in Safety Net Hospital Resulted in Less Frequent Care Refusal for Patients with Breast Cancer
December 14, 2020
Article
A poster presented at the 2020 San Antonio Breast Cancer Symposium found a trend towards less frequent care refusal when a safety net hospital introduced nurse breast navigators.
FDA Grants Priority Review to Nivolumab Plus Ipilimumab to Treat NSCLC
April 08, 2020
Article
Bristol Myers Squibb recently announced that the FDA granted priority review to nivolumab plus ipilimumab in combination with chemotherapy as a first-line treatment for metastatic NSCLC.